Cubist Systematic Strategies’s Krystal Biotech KRYS Stock Holding History

Cubist Systematic Strategies’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,189	Closed	-$1.28M	–	3522
2024 Q1	$1.28M	Buy	+7,189	New	+$999K	0.01%	1971
2023 Q2	–	Sell	-1,300	Closed	-$104K	–	3934
2023 Q1	$104K	Buy	+1,300	New	+$102K	﹤0.01%	3434
2022 Q3	–	Sell	-37	Closed	-$2K	–	4582
2022 Q2	$2K	Hold	37	–	–	﹤0.01%	4318
2022 Q1	$2K	Sell	37 -4,477	-99%	-$279K	﹤0.01%	3514
2021 Q4	$316K	Buy	4,514 +554	+14%	+$32.2K	﹤0.01%	2758
2021 Q3	$207K	Buy	+3,960	New	+$234K	﹤0.01%	2567
2021 Q2	–	Sell	-48	Closed	-$4K	–	3001
2021 Q1	$4K	Buy	+48	New	+$3.49K	﹤0.01%	2792
2020 Q4	–	Sell	-200	Closed	-$9K	–	2636
2020 Q3	$9K	Buy	+200	New	+$8.69K	﹤0.01%	2437
2019 Q2	–	Sell	-500	Closed	-$16K	–	2521
2019 Q1	$16K	Buy	+500	New	+$11.8K	﹤0.01%	2179

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cubist Systematic Strategies's KRYS Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 7,189 shares — an estimated $1.28M sold.

Cubist Systematic Strategies first reported a position in KRYS in Q1 2019 and held it in 9 quarters. The position peaked at $1.28M in Q1 2024. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

Cubist Systematic Strategies reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 7,189 Krystal Biotech shares in Q2 2024, an estimated $1.28M.
Cubist Systematic Strategies first reported a position in Krystal Biotech in Q1 2019 and held it in 9 quarters.
Cubist Systematic Strategies's Krystal Biotech position peaked at $1.28M in Q1 2024.
245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.